Results 191 to 200 of about 86,778 (305)

Comparative Utility of B-type Natriuretic Peptide (BNP) and N-terminal Pro-BNP (NT-proBNP) in the Management of Acute Heart Failure: A Study From a Tertiary Care Hospital in Kashmir, India. [PDF]

Cureus
Ganie JA, Lone HH, Ul Islam M, Ismail M, Nargis S, Farooq A, Muntazir M.   +6 more
europepmc   +1 more source

Underdiagnosed and Undertreated: Obesity and Its Cardiometabolic Burden in Swedish Clinical Practice—Insights From the AROS Database

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To quantify real‐world diagnosis and treatment of obesity in Sweden, describe cardiometabolic comorbidity burden across obesity classes, and compare long‐term cardiovascular outcomes with the general population. Materials and Methods This population‐based cohort study used the AROS (Analysis of Real‐world data of patients with Obesity in ...
Viveca Ritsinger, Magnus Sundbom, Jonatan Dereke, Åsa Ericsson, Thomas Cars, Maria K. Svensson, Anna Norhammar   +6 more
wiley   +1 more source

Elevated B-type natriuretic peptide levels in pregnant women with hyperemesis gravidarum: a biomarker of cardiac stress? [PDF]

Rev Assoc Med Bras (1992)
Bakırcı M, Sarı N, Yalvaç ES, Göçmen AY.   +3 more
europepmc   +1 more source

Prediabetes, Malignant Ventricular Hypertrophy and Stroke: The SPRINT Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Prediabetes and left ventricular hypertrophy (LVH) are common risk factors in adults with hypertension. Whether their coexistence, particularly in the presence of subclinical myocardial injury or stress (malignant LVH), confers a heightened stroke risk is unknown.
Arnaud D. Kaze, Stephen P. Juraschek, Jordana B. Cohen, Siddharth Singh, Chiadi E. Ndumele, Christie M. Ballantyne, Jarrett D. Berry, Justin B. Echouffo‐Tcheugui   +7 more
wiley   +1 more source

Associations of High-Sensitivity Cardiac Troponin T, D-Dimer, and N-Terminal Pro-B-Type Natriuretic Peptide with Subclinical Cardiovascular Dysfunction in the General Population: A Retrospective Cross-Sectional Study. [PDF]

Vasc Health Risk Manag
Jakubiak GK, Pawlas N, Starzak M, Stanek A, Cieślar G.   +4 more
europepmc   +1 more source

The Effect of Canagliflozin Dose on Renal and Cardiovascular Outcomes in Type 2 Diabetes and High Cardiovascular Risk

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Introduction Pharmacokinetic data suggest a potential dose‐dependent effect of sodium–glucose co‐transporter‐2 (SGLT‐2) inhibitors on surrogate markers of efficacy, but the impact of SGLT‐2 inhibitor dose on renal and cardiovascular outcomes remains uncertain.
Elias John Elenjickal, Frédéric Baroz, Philippe Boileau, Michael A. Tsoukas, Abhinav Sharma, Thomas A. Mavrakanas   +5 more
wiley   +1 more source

Developing a risk score for B-type natriuretic peptide (BNP) ≥ 100 pg/ml levels: the suita study. [PDF]

BMC Cardiovasc Disord
Arafa A, Kato Y, Matsumoto C, Khairan P, Maeda S, Kokubo Y.   +5 more
europepmc   +1 more source

The Effects of Combined Antihypertensive and Antidiabetic Therapies on Cardiovascular Outcomes: A Systematic Review and Meta‐Analysis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Hypertension and diabetes frequently coexist, yet the net clinical impact of intentionally combining antihypertensive (AHTN) and antidiabetic (ADA) therapies on cardiovascular (CV) outcomes is uncertain. Here we quantified the effects of AHTN and ADA co‐therapy on CV and blood pressure (BP)/heart rate (HR) outcomes.
Wan Chin Hsieh, Brandon Michael Henry, István Édes   +2 more
wiley   +1 more source

The Role of Epicardial Fat Thickness and B-type Natriuretic Peptide (BNP)/N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) in Heart Failure Risk Stratification: A Systematic Review. [PDF]

Cureus
Osman Mohamed AA, Bashir Omer SS, Mukhtar M, Mohmmed T, Hussein Mohamed WM, Mohamed Hassan MH, Mohammed Hassan I.   +6 more
europepmc   +1 more source

Cost‐Effectiveness of NT‐proBNP–Guided Cardiovascular Screening in Chinese Adults With Type 2 Diabetes: Real‐World Evidence From the Hong Kong Diabetes Biobank

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Heart failure (HF) is among the most costly and prevalent complications of type 2 diabetes (T2D), with annual incremental healthcare costs reaching US$12800 in Hong Kong. We evaluated the cost‐effectiveness of NT‐proBNP‐guided cardiovascular risk stratification to guide cardioprotective treatment. Materials and Methods We developed a four‐
Abby Q. Y. Li, Benjamin Yarnoff, Claudia H. T. Tam, Juliana C. N. Chan, Ronald C. W. Ma, Juliana N. M. Lui, Hong Kong Diabetes Biobank Study Group   +6 more
wiley   +1 more source